More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag ...
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to ...
Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
Docetaxel remains the standard of care for patients with 2L/3L NSCLC without targetable alterations despite severe neutropenia (>40%) that greatly impair patients’ quality of life. Six recent phase 3 ...
The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in ...
Nuvalent achieved positive data from the phase 1/2 ALKOVE-1 study using NVL-655 for the treatment of patients with ALK-mutant ...
Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell ...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback